Context: Quality of life (QoL) and depression are important patient-reported outcomes in cancer care. However, the relative importance of depression severity in predicting QoL remains unclear due to few methodologically sound studies.
Introduction
Quality of life (QoL) is becoming an increasingly important factor in cancer care, and especially so in palliative care. The World Health Organization defines palliative care as "an approach that improves QoL of patients and their families (…) by means of early identification and impeccable assessment and treatment of pain and other problems (…)". (1) As such, best possible QoL is the main goal of palliative care and optimal symptom management the primary mean to achieve it. Still, the ambiguous concept of QoL is not defined by WHO, leaving its content open to interpretation. In line with the 2006 Food and Drug Administration Guideline, we define QoL as "A general concept that implies an evaluation of the impact of all aspects of life on general well-being". 1 The early integration of palliative care services into standard oncology is a topical issue in present oncology, as reflected by the American Society of Clinical Oncology's (ASCO) Provisional Clinical Opinion. 2 Evidence suggests that patients with advanced cancer benefit in terms of improved symptom management and enhanced QoL when receiving early palliative care. 3 With the increased focus on the early integration of palliative care in oncology, knowledge of what contributes to good QoL among patients with advanced cancer therefore is important in oncology as well as in palliative care. Such knowledge aids the early identification of those at risk of poor QoL, hence informing practice and supporting the development of targeted interventions.
Patients with advanced cancer generally experience multiple symptoms and decreasing functioning as the disease progresses. 4 Yet, only a handful of studies have investigated what contributes to poor QoL among these patients. [5] [6] [7] [8] The few studies that have, report associations between somatic symptoms and poorer QoL. 6 Prognostic factors, such as weight loss, comorbidities and physical functioning are also reported to predict QoL. 5, 6 Systemic inflammation, measured by the modified Glasgow Prognostic Score (mGPS), is yet another prognostic factor associated with . A recent study found physical functioning and increasing systemic inflammation to be associated with worsening of QoL independently of each other 7 .
Depressive disorders in patients with advanced cancer are relatively common, with average prevalence rate estimates of around 15% based on structured clinical interviews or patient-reported measures that include the diagnostic criteria of a depressive disorder. 10, 11 Depression is associated with reduced functional status, lower treatment compliance, prolonged hospitalizations and a greater likelihood for a desire for hastened death. 12, 13 Not only does it affect the intensity of physical symptoms, but the presence of depression also complicates symptom management. 14 Nevertheless, depression in patients with advanced cancer is unrecognized in the clinic, clearly hampering adequate treatment. 15 With regards to studies in advanced cancer patients, the relationship between depression and QoL has mainly been explored in samples of patients at the very end of life. 16, 17 In the general population, depression is consistently found to be a strong predictor of impaired quality of life. 18 We identified very few studies investigating this issue among patients with advanced disease earlier in the trajectory, 8 and these were hampered by limitations. Firstly, as disease progression is associated with lowered QoL, this should be properly considered when investigating determinants of QoL, yet disease severity was only assessed by functional performance. Besides, as the measurement of depression in patients with cancer is challenging, primarily due to the overlap of somatic symptoms of depression and progressive cancer, the assessment of depression is crucial. Depression is often assessed by the Hospital Anxiety and Depression Scale (HADS), 8 but importantly, a review of the HADS as a screening tool of major depression reported a widely varying diagnostic accuracy in mixed cancer populations, in line with other studies in patients with advanced cancer. 19 Due to the methodological shortcomings of the few studies to date, it remains unclear whether depression is associated with, and thus may be contributing to, impairment of quality of life in patients with advanced cancer irrespective of symptoms and other prognostic factors. The aim of the present study, which includes a range of relevant disease and treatment variables, is to examine whether depression contributes to impairment of QoL. It is hypothesized that patients with a poorer prognosis, higher symptom burden and higher depression severity also report poorer quality of life than patients with better prognosis and lower symptom burden and depression levels.
Moreover, we will explore the relative importance of depression severity in predicting QoL in patients with advanced cancer.
Methods

Study design and patients
Data collected for a large international cross-sectional study, the EPCRC-CSA 
Study measurements
Health care personnel collected socio-demographic and medical data, while participants completed a range of patient-reported instruments. Data collection was done directly on touch-sensitive, tablet computers.
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QoL. QoL was measured using the Global Health/QoL sub-scale from the European
Organisation for Research and Treatment of Cancer Quality of Life Core
Questionnaire (EORTC-QLQ-C30), one of the most widely used QoL tools in oncology trials. 23 The Global Health/QoL sub-scale consists of two items evaluating overall health and QoL during the past week (range 0-7) that are summed and converted to a 0-100 score. A higher score indicates better QoL. This QoL measure is useful when the aim is to measure the patients' perceived overall QoL 24 and
showed good internal consistency in our sample (Cronbach's α= 0.83).
Medical status: Medical status was assessed based on primary cancer diagnosis (breast cancer, pulmonary cancer, gastrointestinal cancer, male genital cancers and all others), and current disease status: loco-regionally advanced or metastatic disease (Table 1) . 26 Self-reported weight change over the last six months was also included as a prognostic factor (self-reported weight six months ago minus current self-reported weight).
Current treatment:
Symptom burden: Symptom burden was measured using three somatic symptoms from the Edmonton Symptom Assessment Scale (ESAS); nausea, lack of appetite and shortness of breath. The items on psychological symptoms and the item on overall Quality of life were not included in the analyses due to content overlap with depression and overall Quality of life. Each symptom in the ESAS is scored on a scale from 0 (e.g. no lack of appetite) to 10 (e.g. worst possible lack of appetite). 27 Pain was measured by one question from the Brief Pain Inventory (BPI) 28 "pain at its worst during the last 24 hours". The item is rated on an 11-point numerical scale where 0 is "no pain at all" and 10 is "worst possible pain".
Depressive symptom severity: Depressive symptoms were assessed using the PHQ-9, a self-report questionnaire commonly used in medically ill samples, including cancer patients. 11 29 The PHQ-9 items correspond to the DSM-5 diagnostic criteria for major depressive disorder (MDD) and assess the frequency at which they have been bothersome during the past two weeks: 0="not at all", 1="several days", 2="more than half the days" and 3="nearly every day". Symptom severity, however, is measured by summing the scores on all nine items. 30, 31 We have previously shown in this sample that the sum-score is likely conflated by high scores on somatic symptoms of depression that commonly overlap with symptoms of advanced cancer disease. 11 To avoid artificial inflation of any relationships between depressive symptoms severity and QoL in this study, we excluded the somatic PHQ-9 items and summed the scores on the five non-somatic items (depressed mood, anhedonia, feeling of worthlessness, poor concentration and thoughts about death/self-harm). Scores ranged from 0-18, with a higher score indicating higher depression symptom severity. The PHQ-9 showed acceptable internal consistency in our sample (Cronbach's α= 0.79).
Statistical methods
Chi-square, independent group t-tests and Mann-Whitney U tests were used to compare differences between groups of patients included and not included in the study. Variables to be included in the multivariate models were determined using bivariate regression models with statistical significance set at p<0.10. Candidate variables were: medical status variables, current treatment variables, prognostic factors, symptom burden variables and depression. Demographic variables were controlled for in the multivariate models. Multivariate, hierarchical regression was used to explore the relationships between the above-mentioned variables and QoL.
This method allowed us to estimate the unique variance accounted for in the QoL scores by the groups of variables. P-values<0.05 were considered statistically significant. Statistical analyses were done using IBM-SPSS 22 (Armonk, NY: IBM Corp.).
Ethical considerations
The study was performed according to the Helsinki declaration. Ethical approval was obtained at each site before study start. All participants gave their written informed consent.
Results
Sample characteristics
Sample characteristics and comparisons between those included (n=563) or not (n=488) in the sample are provided in Table 1 ). There were no significant differences in QoL scores, age, marital status and haemoglobin levels between the included and notincluded.
Associations with QoL
Univariate models. The univariate models are presented in 
Discussion
To our knowledge the present study is the first to tease apart the relative importance Although highly treatable 32 , it is well documented that both doctors and nurses fail to detect emotional distress and patients themselves rarely disclose unless asked. 15 Further, anti-depressive medication is often started too late to have a benefit. 33 Given that the main aim of palliative care is to ensure the best possible QoL 34 , our results emphasize the clinical importance of detecting and treating depressive symptoms early in the disease trajectory.
Combined, the prognostic factors accounted for 7.6% of the variance in the QoL scores. Both increased systemic inflammation and poorer physical performance status remained significantly associated with poorer QoL in the multivariate models, confirming their importance for QoL in diseased populations. 5, 6 Sociodemographic variables that predict QoL in the general population 35 were not associated with QoL scores in our sample (i.e. age, gender, marital status and education). The literature on the importance of sociodemographic variables for QoL among advanced cancer patients is inconclusive. Some studies report no or only minimal effects of demographic variables. For example, Lundh and colleagues found that being married was associated with lower QoL, while Jordhoy and colleagues found no influence from a live-in partner. 5, 36 In line with our findings, it seems that the overall influence of sociodemographic characteristics on QoL amongst severely diseased patients is superseded by their disease status. 5 To avoid artificially conflating the relationship between depression severity and QoL, we used a modified depression measure that included only the emotional and cognitive symptoms of depression. It is therefore hard to compare the reported depression severity and levels of QoL in our sample with those found in the existing literature. However, the prevalence rate for major depression defined according to the DSM-V diagnostic criteria in the present sample was 11%. This is similar to that reported in a meta-analysis of studies diagnosing major depression based on structured clinical interviews (14.3% (95%CI: 11.1 -17.9). 10 The mean QoL score of 50.5 is comparable to that reported in similar patient groups. 24 The corresponding numbers for the general population are 5-6% and 75, for depression 37 and QoL, 38 respectively.
Study strengths and limitations
The study has some limitations, notably its cross-sectional design which prevents us from making claims of causality between the variables. Further, as our model focuses on disease and treatment, psychosocial variables were not included, such as social support, which are likely to contribute to QoL. In addition, associations between some variables may be conflated due to the common method of measurement used, i.e.
common-method variance. However, excluding the somatic symptoms from our depression measure and including objective indicators of prognosis and observerrated measures of physical functioning, which is rarely done in research to date, should reduce this problem. Further, due to ethical regulations, we lack information about patients who were not invited or declined participation. Additionally, our sample reported significantly higher KPS scores and lower levels of systemic inflammation, loss of appetite, pain and depression severity than those not included. Thus, the most severely diseased patients are not likely to be included in our sample. In line with this, the depression prevalence reported on a slightly different part of the EPCRC-CSA sample was somewhat greater than the 11% reported here. 11 Further, our measure of depression is based on self-report rather than on a diagnostic interview. Nevertheless, the PHQ-9 corresponds to the criteria used in the gold standard (the SCID-MDD interview) and is recommended as a screening tool for depression by the ASCO 39 . Lastly, the data was collected during 2008-2009. As such current treatments may produce slightly different symptom profiles than that described in our sample.
Strengths of this study are firstly that it represents a large international sample of patients with advanced cancer. Second, the sample is well characterized on a broad range of clinically relevant variables. The sample's heterogeneity therefore strengthens the generalizability of our observational design. Many studies do not differentiate between signs and symptoms of disease burden, despite the defined distinction between a subjective experience and an objective indicator. 40 Hence, these results add to the literature by suggesting that not only subjective symptoms, but also objective indicators of disease burden contribute to impaired QoL.
In this large, well characterized sample of patients with advanced cancer, we found that the severity of depression had by far the strongest impact on patients' QoL, irrespective of disease factors, prognostic factors and symptom burden. As such, our findings serve as reminder of the essential role that attention to psychological symptoms plays in the care of advanced cancer patients. There is a need for improvement in our efforts to detect and treat depressive symptoms. 
Included Not included
Categorical variables n % n % Co-morbidities: Heart disease, Arthritis, COPD, renal-and liver disease and other. Symptom burden: Nausea, loss of appetite and shortness of breath were measured by ESAS. Worst pain severity during the last 24 hours by the Brief Pain Inventory.
Higher scores indicate higher symptom burden. 8 Depression severity = sum score of all non-somatic items (depressed mood, anhedonia, guilt, trouble concentrating and suicidal ideations)
